• Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. • Insilico reached the first R&D milestone using its proprietary ...

• Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, ...

Insilico has a connected set of capabilities for adapting AI to scientific work. MMAI Gym develops specialized models; benchmarking helps researchers assess their performance; Generative Biologics, ...

The convergence of frontier artificial intelligence, large-scale biological data, and pharmaceutical innovation is opening new possibilities for understanding human aging, predicting disease, and ...

Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the ...

Insilico Medicine has successfully created a unique approach to identifying potential therapeutic dual-purpose targets for aging and age-associated diseases with its PandaOmics software — an ...

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage ...

Liquid AI and Insilico Medicine today announced a partnership that creates lightweight scientific foundation models for pharmaceutical research. The collaboration has produced LFM2-2.6B-MMAI (v0.2.1), ...

FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico’s first FTD, recognizing the clinical potential in advanced mesothelioma.

Combines Insilico’s Pharma.AI platform with Bora’s global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model Insilico Medicine ( ...

On the evening of March 29, 2026, Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced its ...

Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors Cambridge, MA — July 27, 2026 — Insilico ...